Information about Ethan Basch's clinical work and patient appointment availability.

Current Research Interests

Dr. Ethan Basch's research focuses on the use of patient-reported outcomes (PROs) to assess drug toxicity and symptom endpoints in cancer treatment trials and routine care. He leads a National Cancer Institute initiative to create a patient version of the standard lexicon for adverse event reporting in oncology trials, the Common Terminology Criteria for Adverse Events (PRO-CTCAE). This project involves coordination of a multi-site consortium of cancer centers and community sites, and conduct of four multicenter trials. In 2009, he published papers assessing relationships between patient-reported toxicities and survival in the Journal of the National Cancer Institute and Annals of Oncology. Presentations on PROs this year included a plenary session at the International Society for Quality of Life Research (ISOQOL), Grand Rounds at M.D. Anderson Cancer Center, and talks at the NCI, Drug Information Association, and caBIG annual meeting. In October he was appointed as Chair of the CALGB Quality of Life Committee, and as incoming Chair for 2010 of the ASCO Health Services Committee. Dr. Basch's research is funded by grants from ASCO and the NCI.

Selected Publications

1. Coons SJ, Gwaltney CJ, Hays RD, Lundy JJ, Sloan JA, Revicki DA, Lenderking WR, Cella D, Basch E. Recommendations on Evidence Needed to Support Measurement Equivalence Between Electronic And Paper-Based Patient-Reported Outcome (PRO) Measures. Value Health 2009;12(4):419-429.

2. Basch E, Goldfarb S. Electronic patient-reported outcomes for collecting sensitive information from patients. J Support Oncol 2009;7(3):98-99.

3. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009;7(1):51-7.

4. Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S; Culkin A, Kris MG, Schrag D. Adverse symptom reporting by patients versus clinicians: relationships with clinical outcomes. J Nat Cancer Inst 2009; 101(23):1-9.

5. Atkinson TM, Mendoza TR, Sit L, Passik S, Scher HI, Cleeland C, Basch E. The Brief Pain Inventory and Its "Pain At Its Worst in the Last 24 Hours" Item: Clinical Trial Endpoint Considerations. Pain Med. 2009 Dec 16. [Epub ahead of print]

6. Basch E. Patient-reported outcomes in drug safety evaluation. Ann Oncol. 2009 Dec;20(12):1905-6.

7. Wang XS, Shi Q, Lu C, Basch EM, Johnson VE, Mendoza TR, Mobley GM, Cleeland CS. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010 Jan 1;116(1):137-45.